Clinasia : Phase IV | Phase iv Clinical Trials

Services >> Phase IV


	Phase IV

	Our clinical experience in product development ensures collaboration and integration from pre-approval to post-approval. We provide a custom-tailored process, fine-tuned across the globe, to meet local regulatory requirements. Our operational model is based on a robust technology platform to support remote centralized management of our clients' sites, and our operating procedures are designed for a post-approval setting.


	Early Post-Approval Planning ClinAsia Labs team helps its client in post approval planning in manufacturing and go to market strategies. Product Safety and Pharmacovigilance The team has extensive experience in the collection of safety information for more than 100 products, covering a broad spectrum of therapeutic areas. Late Stage research services. team has helped clients develop and implement late-stage research, including registries and observational studies for more than 10 years. Registries and Observational Studies ClinAsia Labs can help in maintaining registries and conduct observational studies once the product has been approved.

ClinAsia Labs successfully provided services to a fortune 500 pharma company in the area of clinical data management.
-----------------------------------------------
ClinAsia Labs has provided end to end clinical research services in the field of Neurology to a global pharma company.
-----------------------------------------------
ClinAsia Labs has recently completed a study pathology with its expertise in the areas of EDC and Regulatory affairs for a global pharma company.
-----------------------------------------------
ClinAsia Labs successfully provided services to a fortune 500 pharma company in the area of clinical data management.
-----------------------------------------------
ClinAsia Labs has provided end to end clinical research services in the field of Neurology to a global pharma company.
-----------------------------------------------
ClinAsia Labs has recently completed a study pathology with its expertise in the areas of EDC and Regulatory affairs for a global pharma company.
-----------------------------------------------